SIOX
Sio Gene Therapies, Inc. (SIOX)
$0.3172.96%▲
Market is closedMarket is closed – opens on 8 PM, 02 Dec 2022
– opens on 8 PM, 02 Dec 2022
Key Stats
$0.303
Day's Range
$0.335
$0.2303
52-Week Range
$1.53
| Returns | |
| 1 month return | 4.34% |
| 3 month return | 2.46% |
| 1 year return | 78.72% |
| 5 year return | 85.72% |
Company Information
Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Its current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. The company is also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson's disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies.
| Organization | Sio Gene Therapies, Inc. |
| Employees | 12 |
| CEO | Mr. David W. Nassif J.D. |
| Industry | Health Technology |
Analyst Recommendation
based on 6 analysts ratings
Buy
100%
Buy
0%
Hold
0%
Sell
Based on 6 Wall street analysts offering stock ratings for Sio Gene Therapies, Inc.(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 1477.29%Current
$0.32
Target
$5.0
Recommendation Trend
Based on 6 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 6 | 6 | 1 |
| Hold | 0 | 1 | 2 |
| Sell | 0 | 0 | 4 |
| Consensus | BUY | BUY | SELL |
Highlights
| Market Capitalization | 23.5M |
| Book Value | $0.66 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -0.98 |
| Wall Street Target Price | 5.0 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 0.46 |
| Enterprise Value | -27542684 |
| Enterprise Value/Revenue | 0.0 |
| Enterprise Value/Ebitda | 0.56 |
Technicals
| Beta | 1.58 |
| 50 Day MA | 0.3 |
| 200 Day MA | 0.4 |
Institutional Holdings
Rubric Capital Management LP
8.13%
Suvretta Capital Management, LLC
7.99%
Vanguard Group Inc
2.49%
Hudson Bay Capital Management LP
2.27%
Newtyn Management LLC
1.91%
Cladis Investment Advisory LLC
0.75%
Discover more
Frequently Asked Questions
What is Sio Gene Therapies, Inc. share price today?
Can Indians buy Sio Gene Therapies, Inc. shares?
How can I buy Sio Gene Therapies, Inc. shares from India?
Can Fractional shares of Sio Gene Therapies, Inc. be purchased?
What are the documents required to start investing in Sio Gene Therapies, Inc. stocks?
What are today’s High and Low prices of Sio Gene Therapies, Inc.?
What are today’s traded volumes of Sio Gene Therapies, Inc.?
What is today’s market capitalisation of Sio Gene Therapies, Inc.?
What is the 52 Week High and Low Range of Sio Gene Therapies, Inc.?
How much percentage Sio Gene Therapies, Inc. is down from its 52 Week High?
How much percentage Sio Gene Therapies, Inc. is up from its 52 Week low?
What are the historical returns of Sio Gene Therapies, Inc.?
Who is the Chief Executive Officer (CEO) of Sio Gene Therapies, Inc.?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*